Charles River expands discovery services in the U.S. and Europe

The CRO has also built out its PK capabilities near hubs in San Francisco and The Netherlands. (

Charles River Laboratories is expanding its services into the early discovery setting, offering high-speed pharmacokinetics screening of compounds’ underlying biology to help companies identify small-molecule candidates.

The contract research organization has also built out its PK capabilities near pharmaceutical and biotechnology hubs in San Francisco and The Netherlands, the company said. This includes capacity for PK screening regardless of therapeutic area, to support drug discovery from initial testing of potential compounds to late-stage candidate selection and preclinical studies.

“In early discovery research, screening is an essential component of any successful program,” said Birgit Girshick, Charles River’s executive VP for discovery and safety assessment.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

This includes use of a dual-arm autosampler developed by Apricot Designs, for high-throughput absorption, distribution, metabolism and excretion testing.

The system provides an integrated, automated sample delivery platform for liquid chromatography and mass spectrometry, allowing for fast turnaround of permeability, metabolic stability and protein-binding assays.

“The early discovery industry is seeing a marked shift towards a better understanding of the underlying biology of candidate compounds,” said Charles River’s executive director for biology, Ian Waddell.

“Both HT-ADME and PK technologies are critical to that understanding, and to developing more successful candidates in early discovery.”

Suggested Articles reeled in $5 million in series A funding that it plans to use to accelerate lab deployment and expand other features.

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.